The sequential interaction of viral envelope gp120 with CD4 on the cell surface causes the HIV initial infection in the cell. However the gp120 starts producing the antibodies against the complex, but the HIV infection will eludes the immune system. gp120 subunit is key target for producing neutralizing antibodies in HIV-1 isolates.  Many of the researchers have found many challenging methods to elicit neutralizing antibodies against gp120 but they were unable to produce protective antibody. However different clinical trials have been done to produce the HIV vaccine against HIV-1 by targeting epitopes of gp120 and gp41. Indeed initial trails shows poor immunogenic results against these epitopes hence they have design novel immunogenic methods to develop neutralizing epitopes and at present they are mainly focusing on developing anti-gp120 monoclonal antibodies to elicit neutralizing antibodies against cross-reactive V3 epitopes. The complex formed in the cross-reaction has the ability to form neutralizing antibodies with fine specificity and affinity of mAbs and the further improvement will occur by forming the complex with gp120 lacking site-specific N-linked glycans. Thus the increased V3 immunogenicity correlates with enhancement of antibody recognition and proteolytic resistance of V3 epitopes. Thus these studies showed the improved guide lines to produce the potent immunogens not only the prototypic V3 epitopes but also other reactive epitopes on the HIV envelope.

Tags: , ,